Katja N Spreckelmeyer1, Michael Paulzen2, Mardjan Raptis3, Thomas Baltus4, Sabrina Schaffrath2, Julia Van Waesberghe2, Magdalena M Zalewski2, Frank Rösch5, Ingo Vernaleken2, Wolfgang M Schäfer6, Gerhard Gründer2. 1. Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University, and Jülich-Aachen Research Alliance (JARA)-Translational Brain Medicine, Aachen, Germany. Electronic address: kspreckelmeyer@ukaachen.de. 2. Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University, and Jülich-Aachen Research Alliance (JARA)-Translational Brain Medicine, Aachen, Germany. 3. Department of Nuclear Medicine, RWTH Aachen University, Aachen, Germany. 4. Department of Anaesthesiology, RWTH Aachen University, Aachen, Germany. 5. Institute of Nuclear Chemistry, Johannes-Gutenberg-University Mainz, Mainz, Germany. 6. Department of Nuclear Medicine, St. Franziskus Hospital, Mönchengladbach, Germany.
Abstract
BACKGROUND: Preclinical data implicate the reinforcing effects of alcohol to be mediated by interaction between the opioid and dopamine systems of the brain. Specifically, alcohol-induced release of β-endorphins stimulates μ-opioid receptors (MORs), which is believed to cause dopamine release in the brain reward system. Individual differences in opioid or dopamine neurotransmission have been suggested to be responsible for enhanced liability to abuse alcohol. In the present study, a single dose of the MOR agonist remifentanil was administered in detoxified alcohol-dependent patients and healthy control subjects to mimic the β-endorphin-releasing properties of ethanol and to assess the effects of direct MOR stimulation on dopamine release in the mesolimbic reward system. METHODS: Availability of D(2/3) receptors was assessed before and after single-dose administration of the MOR agonist remifentanil in 11 detoxified alcohol-dependent patients and 11 healthy control subjects with positron emission tomography with the radiotracer [(18)F]fallypride. Severity of dependence as assessed with the Alcohol Use Disorders Identification Test was compared with remifentanil-induced percentage change in [(18)F]fallypride binding (Δ%BP(ND)). RESULTS: The [(18)F]fallypride binding potentials (BP(ND)s) were significantly reduced in the ventral striatum, dorsal putamen, and amygdala after remifentanil application in both patients and control subjects. In the patient group, ventral striatum Δ%BP(ND) was correlated with the Alcohol Use Disorders Identification Test score. CONCLUSIONS: The data provide evidence for a MOR-mediated interaction between the opioid and the dopamine system, supporting the assumption that one way by which alcohol unfolds its rewarding effects is via a MOR-(γ-aminobutyric acid)-dopamine pathway. No difference in dopamine release was found between patients and control subjects, but evidence for a patient-specific association between sensitivity to MOR stimulation and severity of alcohol dependence was found.
BACKGROUND: Preclinical data implicate the reinforcing effects of alcohol to be mediated by interaction between the opioid and dopamine systems of the brain. Specifically, alcohol-induced release of β-endorphins stimulates μ-opioid receptors (MORs), which is believed to cause dopamine release in the brain reward system. Individual differences in opioid or dopamine neurotransmission have been suggested to be responsible for enhanced liability to abuse alcohol. In the present study, a single dose of the MOR agonist remifentanil was administered in detoxified alcohol-dependent patients and healthy control subjects to mimic the β-endorphin-releasing properties of ethanol and to assess the effects of direct MOR stimulation on dopamine release in the mesolimbic reward system. METHODS: Availability of D(2/3) receptors was assessed before and after single-dose administration of the MOR agonist remifentanil in 11 detoxified alcohol-dependent patients and 11 healthy control subjects with positron emission tomography with the radiotracer [(18)F]fallypride. Severity of dependence as assessed with the Alcohol Use Disorders Identification Test was compared with remifentanil-induced percentage change in [(18)F]fallypride binding (Δ%BP(ND)). RESULTS: The [(18)F]fallypride binding potentials (BP(ND)s) were significantly reduced in the ventral striatum, dorsal putamen, and amygdala after remifentanil application in both patients and control subjects. In the patient group, ventral striatum Δ%BP(ND) was correlated with the Alcohol Use Disorders Identification Test score. CONCLUSIONS: The data provide evidence for a MOR-mediated interaction between the opioid and the dopamine system, supporting the assumption that one way by which alcohol unfolds its rewarding effects is via a MOR-(γ-aminobutyric acid)-dopamine pathway. No difference in dopamine release was found between patients and control subjects, but evidence for a patient-specific association between sensitivity to MOR stimulation and severity of alcohol dependence was found.
Authors: M Sebold; G Spitta; T Gleich; T Dembler-Stamm; O Butler; K Zacharias; S Aydin; M Garbusow; M Rapp; F Schubert; R Buchert; J Gallinat; A Heinz Journal: J Neural Transm (Vienna) Date: 2019-02-12 Impact factor: 3.575
Authors: Felicia Kamp; Lisa Proebstl; Nora Penzel; Kristina Adorjan; Andrej Ilankovic; Oliver Pogarell; Gabi Koller; Michael Soyka; Peter Falkai; Nikolaos Koutsouleris; Joseph Kambeitz Journal: Neuropsychopharmacology Date: 2018-08-27 Impact factor: 7.853
Authors: Anika A H Alvanzo; Gary S Wand; Hiroto Kuwabara; Dean F Wong; Xiaoqiang Xu; Mary E McCaul Journal: Addict Biol Date: 2015-09-29 Impact factor: 4.280
Authors: Karmen K Yoder; Daniel S Albrecht; Mario Dzemidzic; Marc D Normandin; Lauren M Federici; Tammy Graves; Christine M Herring; Karen L Hile; James W Walters; Tiebing Liang; Martin H Plawecki; Sean O'Connor; David A Kareken Journal: Drug Alcohol Depend Date: 2016-01-13 Impact factor: 4.492
Authors: Joar Guterstam; Nitya Jayaram-Lindström; Simon Cervenka; J James Frost; Lars Farde; Christer Halldin; Johan Franck Journal: Int J Neuropsychopharmacol Date: 2012-08-29 Impact factor: 5.176
Authors: Ben J Watson; Lindsay G Taylor; Alastair G Reid; Sue J Wilson; Paul R Stokes; David J Brooks; James F Myers; Federico E Turkheimer; David J Nutt; Anne R Lingford-Hughes Journal: Addict Biol Date: 2013-07-05 Impact factor: 4.280